



COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

CUPRESSI AETHEROLEUM

SUMMARY REPORT

1. *Cupressi aetheroleum* is the volatile oil obtained from the cones or the leaves and twigs of the tree *Cupressus sempervirens*, also called *Cupressus officinalis*. The cones contain 0.2 to 1% and the branches 0.1% of the volatile oil. Main components of the volatile oil are α -pinene, D-camphene, D-silvestren, p-cymene, L-cadinenes, cedrol, terpinenol-4, terpineol, acetyl- and isovalerianyl monoterpene ester.

Cupressi aetheroleum is also used in human medicine and is extensively used in cosmetics and perfumery.

2. A veterinary product containing 0.8% of the essential oil in combination with seven other essential oils and tinctures is used topically to promote the healing of wounds in cattle, horse, goat, sheep, pig, rabbit and poultry. Wounds are liberally sprayed 3 to 4 times daily with the product until complete healing or applied by means of a wound dressing.
3. *Cupressi aetheroleum* and some of its constituents have anti bacterial and antifungal action *in vitro*. No further information on the pharmacological activity of the volatile oil or its constituents was provided.
4. No toxicological information was available on *Cupressi aetheroleum*. However, its main constituents are present in one or more of the substances of vegetable origin and volatile oils, which were previously assessed by the Committee for Veterinary Medicinal Products and recommended for inclusion in Annex II of Council Regulation (EEC) No 2377/90. A number of them are in addition contained in spices used in the preparation of human food or in the human foodstuffs of vegetable origin. Therefore it was not considered necessary to request further data.
5. *Cupressi aetheroleum* is used in traditional human medicine as an ointment for external use. The essential oil of *Cupressus officinalis* also acts as an expectorant. Besides it was used internally for head colds, coughs and bronchitis.

Health risks or side effects following the proper administration of designated therapeutic dosages in human medicine are not recorded. Kidney irritations are likely with intakes of larger doses of *Cupressi aetheroleum*.

Conclusions and recommendation

Having considered the criteria laid down by the Committee for Veterinary Medicinal Products for inclusion of substances into Annex II of Council Regulation (EEC) 2377/90 in particular that:

- *Cupressi aetheroleum* is used in a small number of individual animals, for infrequent or non-regular treatment,
- *Cupressi aetheroleum* is only used externally,
- treated animals are unlikely to be sent to slaughter during or immediately after treatment;

the Committee for Veterinary Medicinal Products concludes that there is no need to establish an MRL for *Cupressi aetheroleum* and recommends its inclusion in Annex II of Council Regulation (EEC) No 2377/90 in accordance with the following table:

Pharmacologically active substance(s)	Animal species	Other provisions
<i>Cupressi aetheroleum</i>	All food producing species	For topical use only